A new blood-based test to screen for biomarkers of glioblastoma brain cancer has been developed by researchers at Penn State. The test looks for elevated levels of IL13Rα2, an antigen receptor that is derived from glioblastoma tumors.
In glioblastoma brain cancer, EGFR (HER1) genetic mutations lead to a movement of a large part of the extracellular region of the protein. This activates the intracellular area in a particular way that drives glioblastoma tumor development.
Combining machine learning technology with neuroimaging data, clinicians will be better able to fully analyze a patient's glioblastoma brain tumor and predict cancer progression.
A new stem cell therapy approach eliminates established brain tumors and provides long-term immunity, training the immune system to prevent cancer from returning.
Results of a phase three clinical trial of a novel brain cancer vaccine, DCVax-L, that uses a patient's stem cells to target cancer cells extend survival by many months to years for glioblastoma patients.
A new implantable pump system safely and effectively bypasses the blood-brain barrier to deliver chemotherapy drugs to those with glioblastoma brain cancer.
Researchers study the effect of letrozole , a drug designed for the treatment of breast cancer in postmenopausal women, on glioblastoma brain cancer.
A new method that targets the astrocytes surrounding glioblastoma brain cancer eradicates tumor cells and extends lifespan in animal models.
Researchers found a positive correlation between glioblastoma cell proliferation and lactate metabolic indicators. Based on this observation, the researchers developed a biomimetic formulation using targeted delivery agents for lactate metabolism-based synergistic therapy against glioblastoma brain cancer.
Researchers say the gut microbiome may be a viable targetable biomarker to improve immunotherapy responses in those with glioblastoma and a range of other cancers.
Researchers have developed drug-carrying nanoparticles that cross the blood-brain barrier, allowing for more effective delivery to the brain than conventional medications. The nanoparticles can get into tumors and kill glioblastoma brain cancer cells.
Study reveals the ZNF117 gene is a major regulator of glioblastoma tumor cells.
